Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.


Diffuse large B cell lymphomas (DLBCLs) arise from proliferating B cells transiting different stages of the germinal center reaction. In activated B cell DLBCLs (ABC-DLBCLs), a class of DLBCLs that respond poorly to current therapies, chromosomal translocations and amplification lead to constitutive expression of the B cell lymphoma 6 (BCL6) oncogene. The… (More)
DOI: 10.1172/JCI85795


  • Presentations referencing similar topics